S11 Ep48: FDA Approval Insights: Zanidatamab in Pretreated, HER2+ Biliary Tract Cancer

OncLive® On Air - A podcast by OncLive® On Air

Podcast artwork

Dr Harding discusses the significance of the FDA approval of zanidatamab for patients with HER2-positive metastatic biliary tract cancer.